<DOC>
	<DOCNO>NCT01639092</DOCNO>
	<brief_summary>With availability potent nucloes ( ) ide analogue ( NA ) , tenofovir disoproxil fumarate ( TDF ) entecavir ( ETV ) , suppression serum HBV DNA undetectable level polymerase chain reaction ( PCR ) assay become achievable NA treatment-naïve patient . Until recently , however , many patient commence antiviral treatment inferior NAs prior availability TDF ETV , lamivudine ( LAM ) low genetic barrier resistance . ETV resistance increase 51 % patient 5 year ETV treatment lamivudine-refractory patient . Resistance ETV appear occur two-hit mechanism initial selection M204V/I mutation follow amino acid substitution rtT184 , rtS202 , rtM250 . In vitro study show ETV-resistant mutation susceptible TDF , little clinical data efficacy TDF monotherapy patient ETV-resistance . On hand , retrospective cohort study reporting , combination TDF ETV , patient become HBV DNA undetectable median 6 month treatment . Probability reach complete HBV DNA suppression decrease patient ADV ETV-resistance . Thus , consistent treatment recommendation patient ETV-resistance . In clinical trial , investigator clarify whether tenofovir monotherapy effective tenofovir plus entecavir inducing complete virologic response CHB patient genotypic resistance ETV partial virologic response ongoing treatment .</brief_summary>
	<brief_title>Tenofovir vs. Tenofovir Plus Entecavir Entecavir-Resistant Chronic Hepatitis B</brief_title>
	<detailed_description>A multi-center randomized active-controlled open-label trial - Patients randomly assign 1:1 receive tenofovir ( 300 mg/day ) tenofovir ( 300 mg/day ) plus entecavir ( 1 mg/day ) 48 week . - Because 98 % Korean patient CHB HBV genotype C , HBV genotype determine regarded stratification factor . - Patients ' treatment information randomization retrospectively collect . ( DNA change , HBeAg status , HBsAg titre , ALT , treatment duration . etc ) - Patients screen within 4 week randomization determine study eligibility .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>All Compensated liver disease ( ChildPugh class A ) HBsAg positive least 6 month HBeAg positive negative Confirmation resistance mutation Lamivudine ( rtM204V/I and/or rtL180M ) ETV ( rtT184 rtS202 rtM250 ) time screen Serum HBV DNA ≥ 60 IU/mL despite continued precede oral antiviral treatment ( Serum HBV DNA determine PCR assay local laboratory screen study ) Patient ambulatory . Patient willing able comply study drug regimen study requirement . The patient willing able provide write informed consent participate study . Any Patient previously receive TDF 1 week Patient document resistance mutation ADV time screen Patient history hepatocellular carcinoma ( HCC ) finding suggestive possible HCC , suspicious focus image study . In patient finding , HCC ruledout prior randomize patient present study . Patient receive interferon immunomodulatory treatment HBV infection 12 month screen study . Patient concomitant chronic viral infection ( HCV HIV ) Patient evidence renal insufficiency define serum creatinine &gt; 1.5 mg/dL Patient medical condition require concurrent use systemic prednisolone immunosuppressive agent ( include chemotherapeutic agent ) Patient currently abuse alcohol ( 40 g/day ) illicit drug , history alcohol abuse illicit substance abuse within precede two year . Patient pregnant breastfeed willing pregnant Patient one additional know primary secondary cause liver disease , hepatitis B ( e.g. , alcoholism , autoimmune hepatitis , malignancy hepatic involvement , hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's Disease , congenital metabolic condition affect liver , congestive heart failure severe cardiopulmonary disease , etc. ) . A history treat malignancy ( hepatocellular carcinoma ) allowable patient 's malignancy complete remission , chemotherapy without additional surgical intervention , precede three year . Clinical sign decompensated liver disease indicate one following : 1. serum bilirubin &gt; 3 mg/dL 2. prothrombin time &gt; 6 second prolonged INR &gt; 1.5 3. serum albumin &lt; 2.8 g/dL 4 . History ascites , variceal hemorrhage , hepatic encephalopathy 5 . ChildPugh score ≥7</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Resistance Entecavir</keyword>
</DOC>